Urapidil

PreclinicalSmall molecule

UUniversity Hospital, Strasbourg, France

Urapidil is one of 50 small molecule programs targeting Intracerebral Hemorrhage. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracerebral HemorrhageActive, not recruiting

HemodynamicCompleted

Elderly PatientsUnknown status

Intracerebral HemorrhagePreclinical

Active, not recruiting

HemodynamicPreclinical

Completed

Elderly PatientsPreclinical

Unknown status

Competition

Competitive Landscape

34 competitors in Intracerebral Hemorrhage

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Depakote

AbbVie

Approved

1 3

Lovenox

Sanofi

Approved

1 4

Myrbetriq

Cyklokapron

3 6

Normodyne

Olumiant

2 8

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 9

Minocycline /d

UUniversity of Florida

Phase 3

1 10

Recombinant Factor Viia

SSheba Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Intracerebral Hemorrhage

NCT06635707

Clinical

Trials by Indication[1]

Hypertension2 trials

The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine

Terminated·UUniversity Hospital, Strasbourg, France·Phase 3·NCT02558023·14 enrolled

Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine

Unknown status·UUniversity Hospital, Strasbourg, France·Phase 3·NCT00409253·72 enrolled

CLE1 trial

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Withdrawn·UUniversity of Zurich·Phase 4·NCT03300479

Blood Pressure1 trial

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Completed·TThe George Institute·N/A·NCT00226096·404 enrolled

Intracerebral Hemorrhage1 trial

Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage

Not yet recruiting·QQianfoshan Hospital··NCT06635707·600 enrolled

Stroke1 trial

Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

Completed·TThe George Institute for Global Health, China·Phase 3·NCT03790800·2,425 enrolled

2 more indications

Elderly Patients1 trial

Effect of High vs. Low MAP Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery

Unknown status·HHu Anmin·N/A·NCT02857153·322 enrolled

Hemodynamic1 trial

Effects of Different Kinds of Hypotensive Drugs on Dynamic Hemodynamic Changing in Patients Under Surgeries

Completed·—·N/A·NCT03497351·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Urapidil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urapidil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urapidil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Strasbourg, France

Urapidil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hypertension2 trials

CLE1 trial

Blood Pressure1 trial

Intracerebral Hemorrhage1 trial

Stroke1 trial

Elderly Patients1 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News